Hyalos
Biofunctional surface coatings for regenerative medicine applications.
| Date | Investors | Amount | Round |
|---|---|---|---|
N/A | Seed | ||
| Total Funding | 000k | ||
Hyalos is a regenerative medicine company focused on developing cell therapy to treat corneal endothelial disease. The company's primary innovation is a method to cultivate and expand corneal endothelial cells from a single donor cornea to treat multiple patients. This approach addresses the global shortage of donor corneas required for transplant surgeries.
The treatment involves a minimally invasive procedure where cultured allogeneic endothelial cells are injected into the patient's eye. These cells then repopulate the cornea, forming a healthy monolayer that restores vision by reducing corneal edema. This cell therapy offers an alternative to more complex surgical procedures like penetrating and endothelial keratoplasties, potentially eliminating complications such as graft rejection and infection. In March 2023, Aurion Biotech, a company in the same field, received approval in Japan for a similar allogeneic cell therapy, marking a significant milestone for this type of treatment.
The name "Hyalos" is derived from the Greek word for "glass-like," referencing the vitreous humor of the eye from which hyaluronic acid, a key component in ocular health and regenerative medicine, was first isolated.
Keywords: regenerative medicine, cell therapy, corneal endothelial disease, corneal transplant alternative, endothelial dysfunction, ophthalmology, bullous keratopathy, allogeneic cell therapy, corneal edema, vision restoration, eye surgery, donor cornea, tissue engineering, hyaluronic acid, Fuchs dystrophy, keratoplasty alternative